Systemic and Vascular Oxidation Limits the Efficacy of Oral Tetrahydrobiopterin Treatment in Patients With Coronary Artery Disease
Circulation2012Vol. 125(11), pp. 1356–1366
Citations Over TimeTop 10% of 2012 papers
Colin Cunnington, Tim Van Assche, Cheerag Shirodaria, Ilias Kylintireas, Alistair C Lindsay, Justin Lee, Charalambos Antoniades, Marios Margaritis, Regent Lee, Ruha Cerrato, Mark J. Crabtree, Jane M Francis, Rana Sayeed, C Ratnatunga, Ravi Pillai, Robin P. Choudhury, Stefan Neubauer, Keith M. Channon
Abstract
Oral BH4 treatment augments total biopterin levels in patients with established coronary artery disease but has no net effect on vascular redox state or endothelial function owing to systemic and vascular oxidation of BH4. Alternative strategies are required to target BH4-dependent endothelial function in established vascular disease states.
Related Papers
- → A differential microdetermination for the various forms of biopterin(1978)24 cited
- → Determination of tetrahydrobiopterin in murine locus coeruleus by HPLC with fluorescence detection(2001)19 cited
- → Tetrahydrobiopterin and Total Biopterin Content of Neuroblastoma (N1E‐115, N2A) and Pheochromocytoma (PC‐12) Clones and the Dependence of Catecholamine Synthesis on Tetrahydrobiopterin Concentration in PC‐12 Cells(1984)44 cited
- → Influences of Catecholamine Contents on Tetrahydrobiopterin Metabolism(1998)
- → P.5.f.002 Involvement of tetrahydrobiopterin in delirium after cardiac surgery(2009)